Pyrotinib in Combination With Fulvestrant in Patients With HER2 Positive，HR-Positive Metastatic Breast Cancer
Status: UNKNOWN
Study type: INTERVENTIONAL
Conditions: Metastatic Breast Cancer
Interventions: DRUG: Pyrotinib combined with fulvestrant
Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University